Drug Profile
Research programme: ion channel antagonists - Asahi Kasei Pharma/ Evotec SE
Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Asahi Kasei Pharma Corp; Evotec AG
- Developer Asahi Kasei; Evotec SE
- Class
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified